Noteworthy SEC Filing: Pain Therapeutics Inc: Wilmot B. Harkey And Daniel Mack’s Nantahala Capital Management Opened Big New Position

Noteworthy SEC Filing: Pain Therapeutics Inc: Wilmot B. Harkey And Daniel Mack's Nantahala Capital Management Opened Big New Position

The New Wilmot B. Harkey And Daniel Mack’s Nantahala Capital Management Holding in Pain Therapeutics Inc

Nantahala Capital Management filed with the SEC SC 13G/A form for Pain Therapeutics Inc. The form can be accessed here: 000114420416133326. As reported in Wilmot B. Harkey And Daniel Mack’s Nantahala Capital Management’s form, the filler as of late owns 7.4% or 3,429,353 shares of the Health Care–company.

Pain Therapeutics Inc stake is a new one for the for the hedge fund and it was filed because of activity on October 31, 2016. We feel this shows Wilmot B. Harkey And Daniel Mack’s Nantahala Capital Management’s positive view for the stock. For a hedge fund managing $614.40 million in assets and having 10+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.

The hedge fund is active investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Wilmot B. Harkey And Daniel Mack’s Nantahala Capital Management’s US equities portfolio is in this sector.

Pain Therapeutics Inc Institutional Sentiment

Latest Security and Exchange filings show 48 investors own Pain Therapeutics Inc. The institutional ownership in Q3 2015 is low, at 41.34% of the outstanding shares. This is decreased by 1814043 the total institutional shares. 19073689 were the shares owned by these institutional investors. In total 3 funds opened new Pain Therapeutics Inc stakes, 10 increased stakes. There were 18 that closed positions and 20 reduced them.

Gagnon Securities Llc is an institutional investor bullish on Pain Therapeutics Inc, owning 62799 shares as of Q3 2015 for 0.06% of its portfolio. David R Rahn & Associates Inc owns 32637 shares or 0.06% of its portfolio. CT Nantahala Capital Management Llc have 1.13% of their stock portfolio for 4537705 shares. Further, 683 Capital Management Llc reported stake worth 0.12% of its US stock portfolio. The CA Bvf Inc owns 928760 shares. Pain Therapeutics Inc is 0.34% of the manager’s US portfolio.

Business Profile

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company’s drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Wilmot B. Harkey And Daniel Mack’s Nantahala Capital Management website.

Insitutional Activity: The institutional sentiment increased to 1.31 in Q2 2016. Its up 0.44, from 0.87 in 2016Q1. The ratio is positive, as 3 funds sold all Pain Therapeutics, Inc. shares owned while 10 reduced positions. 5 funds bought stakes while 12 increased positions. They now own 22.53 million shares or 0.43% more from 22.44 million shares in 2016Q1.

Blackrock Fund Advsr accumulated 96,513 shares or 0% of the stock. Acadian Asset Management Lc has 0% invested in the company for 351,072 shares. Gamco Invsts Inc Et Al has 65,000 shares for 0% of their US portfolio. D E Shaw & Incorporated holds 0% or 378,601 shares in its portfolio. Brandes Partners Limited Partnership has invested 0% of its portfolio in Pain Therapeutics, Inc. (NASDAQ:PTIE). Manufacturers Life The last reported 483 shares in the company. Blackrock Llc owns 8,736 shares or 0% of their US portfolio. Blackrock Institutional Com Na has 1.30 million shares for 0% of their US portfolio. Tower Research Cap (Trc) has 21,363 shares for 0% of their US portfolio. Morgan Stanley accumulated 1,061 shares or 0% of the stock. Dimensional Fund Advsrs Lp has 0% invested in the company for 665,780 shares. Comml Bank Of America De holds 0% or 30,386 shares in its portfolio. Wells Fargo Com Mn has invested 0% of its portfolio in Pain Therapeutics, Inc. (NASDAQ:PTIE). Goldman Sachs Group Inc has 0% invested in the company for 19,451 shares. Walleye Trading Lc has 1,500 shares for 0% of their US portfolio.

Analysts await Pain Therapeutics, Inc. (NASDAQ:PTIE) to report earnings on November, 14.

The stock increased 8.43% or $0.051 on November 10, hitting $0.651. About 375,128 shares traded hands. Pain Therapeutics, Inc. (NASDAQ:PTIE) has declined 71.76% since April 8, 2016 and is downtrending. It has underperformed by 77.41% the S&P500.

Pain Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $32.09 million. The Firm is focused on drug development efforts on disorders of the nervous system, such as chronic pain. It currently has negative earnings. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone .

Another recent and important Pain Therapeutics, Inc. (NASDAQ:PTIE) news was published by Marketwatch.com which published an article titled: “Pain Therapeutics receives FDA letter saying NDA for opioid analgesic can’t be …” on September 26, 2016.

According to Zacks Investment Research, “Pain Therapeutics is developing a new generation of opioid painkillers. Opioids are drugs derived from the poppy plant. The company uses technology to reformulate opioid drugs, such as morphine, into new painkillers with improved clinical benefits. The company has four opioid painkillers in Phase II clinical trials. The company believes its drugs offer enhanced pain relief, fewer adverse side effects and reduced tolerance and addiction compared to existing opioid painkillers.”

PTIE Company Profile

Pain Therapeutics, Inc., incorporated on May 4, 1998, is a biopharmaceutical firm that develops drugs. The Firm is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment